Liquid Biopsy in the OMICS Era of Tumor Medicine

Yi Jiang and Denong Wang*

Received: March 01, 2018;   Published: March 07, 2018

DOI: 10.32474/OAJBEB.2018.01.000115

Full Text PDF

To view the Full Article   Peer-reviewed Article PDF

Abstract

Liquid biopsy uses noninvasive blood test to assess tumor heterogeneity and evolution in real time. It looks for tumor components in the blood circulation, such as circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA), to provide tumorspecific information. By detecting multiplex tumor biomarkers, including nucleic acids, proteins, carbohydrates, and other tumorderived substances, liquid biopsy helps with early tumor diagnosis, tumor evolution monitoring, and prognosis prediction. With the development of high-throughput OMICS tools like carbohydrate microarray and high-speed fiber-optic array scanning technology (FAST scan), it is now practical to identify glycan markers of CTCs and cancer stem cells(CSCs), especially those that are cell-surface exposed and readily accessible for immune recognition and targeting. Potential of this class of biomarkers in tumor sub typing and targeted immunotherapy is yet to be explored

Keywords: Blood group precursor; Cancer stem cells; Carbohydrate microarray; Circulating tumor cells; Circulating tumor DNA; Glycan markers; Glycomics; Liquid biopsy

Abstract| Introduction| Acknowledgement| References|